10X Genomics Liabilities 2024

10X Genomics Aktienanalyse

What does 10X Genomics do?

10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing 10X Genomics's Liabilities

10X Genomics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating 10X Genomics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing 10X Genomics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

10X Genomics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in 10X Genomics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about 10X Genomics Stock

What is the level of liabilities of 10X Genomics this year?

10X Genomics has a debt balance of 224.1 M USD this year.

What were the liabilities of 10X Genomics compared to the previous year?

The liabilities of 10X Genomics have increased by 0.4% increased compared to the previous year.

What are the consequences of high debt for investors of 10X Genomics?

High liabilities can pose a risk for investors of 10X Genomics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in 10X Genomics?

Low liabilities mean that 10X Genomics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of 10X Genomics affect the company?

An increase in liabilities of 10X Genomics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of 10X Genomics affect the company?

A decrease in the liabilities of 10X Genomics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of 10X Genomics?

Some factors that can influence the liabilities of 10X Genomics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of 10X Genomics so important for investors?

The liabilities of 10X Genomics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can 10X Genomics take to modify the liabilities?

To change its liabilities, 10X Genomics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does 10X Genomics pay?

Over the past 12 months, 10X Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 10X Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of 10X Genomics?

The current dividend yield of 10X Genomics is .

When does 10X Genomics pay dividends?

10X Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 10X Genomics?

10X Genomics paid dividends every year for the past 0 years.

What is the dividend of 10X Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 10X Genomics located?

10X Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von 10X Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 10X Genomics from 4/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/28/2024.

When did 10X Genomics pay the last dividend?

The last dividend was paid out on 4/28/2024.

What was the dividend of 10X Genomics in the year 2023?

In the year 2023, 10X Genomics distributed 0 USD as dividends.

In which currency does 10X Genomics pay out the dividend?

The dividends of 10X Genomics are distributed in USD.